Published 3 months ago

Why Is CymaBay Therapeutics Stock Trading Higher Today? - CymaBay Therapeutics (NASDAQ:CBAY), Gilead Sciences (NASDAQ:GILD)

Summary by Ground News

Gilead Sciences (NASDAQ:GILD) has agreed to acquire CymaBay Therapeutics (NASdaq:CBAY) for a total equity value of $4.3B. The deal is expected to close during the first quarter of 2024, subject to regulatory approvals and other customary closing conditions.

0 Articles

All

Left

Center

Right

Benzinga

Why Is CymaBay Therapeutics Stock Trading Higher Today? - CymaBay Therapeutics (NASDAQ:CBAY), Gilead Sciences (NASDAQ:GILD)

Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio. “We are looking forward to advancing seladelpar by leveraging Gilead’s long-standing expertise in treating…

3 months ago·New York, United States

Read Full Article